Mark Greene

Brief DescriptionMonoclonal antibody and immunotherapy use in prostate cancerDocket # V5084Technology OverviewBoth androgen dependent and independent prostatic carcinomas have a high potential to metastasize; unfortunately, the overall 5-year survival rate for metastatic prostate cancer is only 34%....

Market OverviewWorldwide cancer affects approximately 10 million people each year and it is expected to increase to 15 million by 2020. Worldwide approximately 23 million people are living with cancer and about 5.2 million people die. Breast cancer is the most common cancer among women with 1.2 mill...

Technology OverviewRoughly 12 million patients are exposed to heparin annually and up to 1% of these patients will develop heparin-induced thrombocytopenia/thrombosis (HIT), a life-threatening complication where patients make antibodies that bind to the heparin/PF4 complex, resulting in thrombosis a...

Cancer affects approximately 10 million people globally, with breast and lung cancer accounting for 25% of cancer incidences. Assuming over expression of Her2 is responsible for 25% of the breast cancer and lung cancer, and then the estimated market is about one million. The estimated price of Lapat...

Technology Overview:Roughly 12 million patients are exposed to heparin annually and up to 1% of these patients will develop heparin-induced thrombocytopenia/thrombosis (HIT), a life-threatening complication where patients make antibodies that bind to the heparin/PF4 complex, resulting in thrombosis ...

Monoclonal antibody and immunotherapy use in prostate cancerTechnology Overview:Both androgen dependent and independent prostatic carcinomas have a high potential to metastasize. Unfortunately, the overall 5-year survival rate for metastatic prostate cancer is only 34%.Dr. Greene and his collaborato...

Technology Overview:While antibody therapeutics have proven to be successful in recent years, they are not without drawbacks. The large size of antibodies can prevent their effective use against certain cancers, as well as prevent them from crossing the blood-brain barrier. Additionally, many antibo...